Amar Kishan, MD’s PubMed Publications – 2015-2020

  1. Parikh NR, Tsai S, Bennett C, Lewis M, Sadeghi A, Lorentz W, Cheung M, Garraway I, Aronson W, Kishan AU, Bahri S, Vahidi K, Calais J, Ishimitsu D, Rettig M, Nickols NG, Jafari L.  The Impact of 18 F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer.  Adv Radiat Oncol. 2020 Sep 9;5(6):1364-1369. doi: 10.1016/j.adro.2020.08.014. eCollection 2020 Nov-Dec. PMID: 33305100
  2. Qi XS, Chu FI, Zhang Z, Chin RK, Raldow A, Kishan AU, Lee P, Chang A, Kalbasi A, Kamrava M, Steinberg ML, Low DA.  Clinical Development and Evaluation of Megavoltage Topogram for Fast Patient Alignment on Helical Tomotherapy.  Adv Radiat Oncol. 2020 Jun 17;5(6):1334-1341. doi: 10.1016/j.adro.2020.05.014. eCollection 2020 Nov-Dec. PMID: 33305096
  3. Jairath NK, Dal Pra A, Vince R Jr, Dess RT, Jackson WC, Tosoian JJ, McBride SM, Zhao SG, Berlin A, Mahal BA, Kishan AU, Den RB, Freedland SJ, Salami SS, Kaffenberger SD, Pollack A, Tran P, Mehra R, Morgan TM, Weiner AB, Mohamad O, Carroll PR, Cooperberg MR, Karnes RJ, Nguyen PL, Michalski JM, Tward JD, Feng FY, Schaeffer EM, Spratt DE.  A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer.  Eur Urol. 2020 Dec 5:S0302-2838(20)30885-X. doi: 10.1016/j.eururo.2020.11.021. Online ahead of print. PMID: 33293078
  4. Ma TM, Lilleby O, Lilleby WA, Kishan AU.  Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy.   Cancers (Basel). 2020 Dec 2;12(12):E3606. doi: 10.3390/cancers12123606. PMID: 33276562
  5. Dee EC, Muralidhar V, Arega MA, Kishan AU, Spratt DE, Dess RT, King MT, Sha ST, Santos PMG, Butler SS, Sanford NN, Nguyen PL, Mahal BA.  Factors influencing non-completion of radiotherapy among men with localized prostate cancer.  Int J Radiat Oncol Biol Phys. 2020 Dec 1:S0360-3016(20)34604-6. doi: 10.1016/j.ijrobp.2020.11.064. Online ahead of print. PMID: 33276019 
  6. Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson WC, Hartman HE, Kishan AU, Mehra R, Kaffenberger S, Morgan TM, Reichert ZR, Alumkal JJ, Michalski J, Lee WR, Pisansky TM, Feng FY, Shipley W, Sandler HM, Schipper MJ, Roach M, Sun Y, Lawton CAF.  Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.  J Clin Oncol. 2020 Dec 4:JCO2002438. doi: 10.1200/JCO.20.02438. Online ahead of print. PMID: 33275486 
  7. Cook K, Kishan AU. Pelvic nodal radiotherapy in Gleason grade group 5 prostate cancer.  Transl Androl Urol. 2020 Oct;9(5):2326-2328. doi: 10.21037/tau-20-917. PMID: 33209705
  8. Kishan AU, Sandler HM. Local failure in high grade prostate cancer: the importance of local and systemic therapy.  Transl Androl Urol. 2020 Oct;9(5):2315-2317. doi: 10.21037/tau-20-910. PMID: 33209704
  9. Tong N, Gou S, Chen S, Yao Y, Yang S, Cao M, Kishan AU, Sheng K.  Multi-task edge-recalibrated network for male pelvic multi-organ segmentation on CT images.  Phys Med Biol. 2020 Nov 16. doi: 10.1088/1361-6560/abcad9. Online ahead of print. PMID: 33197901 
  10. Patel SA, Switchenko JM, Kishan AU, Jani AB, Royce TJ, Fischer-Valuck BW.  Stereotactic body radiation therapy use for high risk prostate cancer in the United States.  Prostate Cancer Prostatic Dis. 2020 Nov 13. doi: 10.1038/s41391-020-00300-5. Online ahead of print. PMID: 33188271 
  11. Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, Chen R, Choudhury A, Henry A, Syndikus I, Mitin T, Tree A, Kishan AU, Spratt DE.  Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19.   Adv Radiat Oncol. 2020 Oct 29;5(Suppl 1):26-32. doi: 10.1016/j.adro.2020.10.003. eCollection 2020 Nov. PMID: 33145460  
  12. Dinh TT, Mitin T, Bagshaw HP, Hoffman KE, Hwang C, Karnes RJ, Kishan AU, Liauw SL, Lloyd S, Potters L, Showalter TN, Taira AV, Vapiwala N, Zaorsky NG, D'Amico AV, Nguyen PL, Davis BJ.   Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer.  Int J Radiat Oncol Biol Phys. 2020 Oct 27:S0360-3016(20)34448-5. doi: 10.1016/j.ijrobp.2020.10.031. Online ahead of print. PMID: 33127490
  13. Cao M, Stiehl B, Yu VY, Sheng K, Kishan AU, Chin RK, Yang Y, Ruan D.   Analysis of Geometric Performance and Dosimetric Impact of Using Automatic Contour Segmentation for Radiotherapy Planning.  Front Oncol. 2020 Sep 23;10:1762. doi: 10.3389/fonc.2020.01762. eCollection 2020. PMID: 33102206
  14. Kishan AU, Nickols NG, Spratt DE. Prostate-specific Membrane Antigen Positron Emission Tomography-guided Radiotherapy.  Eur Urol Focus. 2020 Oct 10:S2405-4569(20)30283-2. doi: 10.1016/j.euf.2020.09.020. Online ahead of print. PMID: 33046413
  15. Levin-Epstein RG, Jiang NY, Wang X, Upadhyaya SK, Collins SP, Suy S, Aghdam N, Mantz C, Katz AJ, Miszczyk L, Napieralska A, Namysl-Kaletka A, Prionas N, Bagshaw H, Buyyounouski MK, Cao M, Agazaryan N, Dang A, Yuan Y, Kupelian PA, Zaorsky NG, Spratt DE, Mohamad O, Feng FY, Mahal BA, Boutros PC, Kishan AU, Juarez J, Shabsovich D, Jiang T, Kahlon S, Patel A, Patel J, Nickols NG, Steinberg ML, Fuller DB, Kishan AU.  Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control.  Radiother Oncol. 2020 Oct 7;154:207-213. doi: 10.1016/j.radonc.2020.09.053. Online ahead of print. PMID: 33035622 
  16. Singhrao K, Fu J, Parikh NR, Mikaeilian AG, Ruan D, Kishan AU, Lewis JH.  A Generative Adversarial Network-Based (GAN-Based) Architecture for Automatic Fiducial Marker Detection in Prostate MRI-Only Radiotherapy Simulation Images.  Med Phys. 2020 Sep 28. doi: 10.1002/mp.14498. Online ahead of print. PMID: 32989773 
  17. Zaorsky NG, Spratt DE, Kishan AU, Culp SH, Showalter TN. Editorial: Optimizing Local Therapy for High-Risk Prostate Cancer: Evidence and Emerging Options.  Front Oncol. 2020 Aug 27;10:1616. doi: 10.3389/fonc.2020.01616. eCollection 2020. PMID: 32984028
  18. Nguyen KA, Lee A, Patel SA, Chakravorty A, Yu JB, Kishan AU, Chang AJ.  Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer.  JAMA Netw Open. 2020 Sep 1;3(9):e2017144. doi: 10.1001/jamanetworkopen.2020.17144. PMID: 32970153
  19. Parikh NR, Chang EM, Kishan AU, Kaprealian TB, Steinberg ML, Raldow AC.  Time-Driven Activity-Based Costing Analysis of Telemedicine Services in Radiation Oncology.  Int J Radiat Oncol Biol Phys. 2020 Oct 1;108(2):430-434. doi: 10.1016/j.ijrobp.2020.06.053. PMID: 32890526
  20. Fendler WP, Calais J, Eiber M, Simko JP, Kurhanewicz J, Santos RD, Feng FY, Reiter RE, Rettig MB, Nickols NG, Kishan AU; PSMA PET Reader Group, Slavik R, Carroll PR, Lawhn-Heath C, Herrmann K, Czernin J, Hope TA. False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial.  Eur J Nucl Med Mol Imaging. 2020 Aug 17. doi: 10.1007/s00259-020-04945-1. Online ahead of print. PMID: 32808077 
  21. Hu Q, Yu VY, Yang Y, Hu P, Sheng K, Lee PP, Kishan AU, Raldow AC, O'Connell DP, Woods KE, Cao M.  Practical Safety Considerations for Integration of Magnetic Resonance Imaging in Radiation Therapy. Pract Radiat Oncol. 2020 Aug 8:S1879-8500(20)30202-2. doi: 10.1016/j.prro.2020.07.008. Online ahead of print. PMID: 32781246
  22. Levin-Epstein R, Cook RR, Wong JK, Stock RG, Jeffrey Demanes D, Collins SP, Aghdam N, Suy S, Mantz C, Katz AJ, Nickols NG, Miszczyk L, Napieralska A, Namysl-Kaletka A, Prionas ND, Bagshaw H, Buyyounouski MK, Cao M, Mahal BA, Shabsovich D, Dang A, Yuan Y, Rettig MB, Chang AJ, Jackson WC, Spratt DE, Lehrer EJ, Zaorsky NG, Kupelian PA, Steinberg ML, Horwitz EM, Jiang NY, Kishan AU.  Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.  Radiother Oncol. 2020 Jul 11;151:26-32. doi: 10.1016/j.radonc.2020.07.014. Online ahead of print. PMID: 32663537 
  23. Nickols NG, Ganapathy E, Nguyen C, Kane N, Lin L, Diaz-Perez S, Nazarian R, Mathis C, Felix C, Basehart V, Zomorodian N, Kwak J, Kishan AU, King CR, Kupelian PA, Rettig MB, Steinberg ML, Cao M, Knudsen BS, Chu FI, Romero T, Elashoff D, Reiter RE, Schaue D.  The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells.  Prostate Cancer Prostatic Dis. 2020 Jul 9. doi: 10.1038/s41391-020-0249-8. Online ahead of print. PMID: 32647353 
  24. Parikh NR, Kishan AU, Kane N, Diaz-Perez S, Ganapathy E, Nazarian R, Felix C, Mathis C, Bradley M, Sachdeva A, Wyatt B, Basehart V, Zomorodian N, Lin L, King CR, Kupelian PA, Rettig MB, Steinberg ML, Cao M, Knudsen BS, Elashoff D, Schaue D, Reiter RE, Nickols NG.  Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer.  Int J Radiat Oncol Biol Phys. 2020 Jun 17:S0360-3016(20)31251-7. doi: 10.1016/j.ijrobp.2020.06.010. Online ahead of print. PMID: 32562839 
  25. Parikh NR, Chang EM, Nickols NG, Rettig MB, Raldow AC, Steinberg ML, Koontz BF, Vapiwala N, Deville C, Feng FY, Spratt DE, Reiter RE, Phillips R, Ost P, Tran PT, Kishan AU.  Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.  Int J Radiat Oncol Biol Phys. 2020 Jun 13:S0360-3016(20)31250-5. doi: 10.1016/j.ijrobp.2020.06.009. Online ahead of print. PMID: 32544574 
  26. Dang AT, Levin-Epstein RG, Shabsovich D, Cao M, King C, Chu FI, Mantz CA, Stephans KL, Reddy CA, Loblaw DA, Cheung P, Scorsetti M, Cozzi L, DeNittis AS, Wang Y, Zaorsky N, Nickols NG, Kupelian PA, Steinberg ML, Kishan AU.  Gantry-Mounted Linear Accelerator-Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer.  Adv Radiat Oncol. 2019 Oct 14;5(3):404-411. doi: 10.1016/j.adro.2019.09.010. eCollection 2020 May-Jun. PMID: 32529134
  27. Valle LF, Ruan D, Dang A, Levin-Epstein RG, Patel AP, Weidhaas JB, Nickols NG, Lee PP, Low DA, Qi XS, King CR, Steinberg ML, Kupelian PA, Cao M, Kishan AU.   Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following. Prostate Cancer Stereotactic Body Radiotherapy.  Front Oncol. 2020 May 20;10:786. doi: 10.3389/fonc.2020.00786. eCollection 2020. PMID: 32509582
  28. Lehrer EJ, Kishan AU, Yu JB, Trifiletti DM, Showalter TN, Ellis R, Zaorsky NG.  Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials.  Radiother Oncol. 2020 Jul;148:235-242. doi: 10.1016/j.radonc.2020.04.037. Epub 2020 Apr 28. PMID: 32505965 
  29. Parikh NR, Kishan AU.  Stereotactic Body Radiotherapy for Prostate Cancer.  Am J Mens Health. 2020 May-Jun;14(3):1557988320927241. doi: 10.1177/1557988320927241. PMID: 32500805      Prostate cancer remains the most common and second most deadly cancer diagnosed amongst U.S. men. External beam radiotherapy is a standard-of-care definitive treatment option for localized prostate cancer and historically constituted an 8-9-week treatment course comprised … 
  30. Kishan AU, Romero T, Alshalalfa M, Liu Y, Tran PT, Nickols NG, Ye H, Sajed D, Rettig MB, Reiter RE, Garraway IP, Spratt DE, Freedland SJ, Zhao X, Li Z, Deek M, Livingstone J, Mahal BA, Nguyen PL, Feng FY, Den RB, Schaeffer EM, Lotan TL, Karnes RJ, Klein EA, Ross AE, Grogan T, Davicioni E, Elashoff D, Boutros PC, Weidhaas JB. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer.  Eur Urol. 2020 Sep;78(3):327-332. doi: 10.1016/j.eururo.2020.05.009. Epub 2020 May 24. PMID: 32461072 
  31. Sonni I, Caron J, Kishan AU, Muthusamy VR, Calais J. PSMA Expression in the Neovasculature Associated With Rectal Adenocarcinoma: A Potential Stromal Target for Nuclear Theranostics.  Clin Nucl Med. 2020 Jul;45(7):e309-e310. doi: 10.1097/RLU.0000000000003066. PMID: 32404709 
  32. Jackson WC, Hartman HE, Dess RT, Birer SR, Soni PD, Hearn JWD, Reichert ZR, Kishan AU, Mahal BA, Zumsteg ZS, Efstathiou JA, Kaffenberger S, Morgan TM, Mehra R, Showalter TN, Krauss DA, Nguyen PL, Schipper MJ, Feng FY, Sandler HM, Hoskin PJ, Roach M 3rd, Spratt DE.  Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.  J Clin Oncol. 2020 Sep 10;38(26):3024-3031. doi: 10.1200/JCO.19.03217. Epub 2020 May 12. PMID: 32396488 
  33. Pan X, Levin-Epstein R, Huang J, Ruan D, King CR, Kishan AU, Steinberg ML, Qi XS.  Dosimetric predictors of patient-reported toxicity after prostate stereotactic body radiotherapy: Analysis of full range of the dose-volume histogram using ensemble machine learning.  Radiother Oncol. 2020 Jul;148:181-188. doi: 10.1016/j.radonc.2020.04.013. Epub 2020 Apr 17. PMID: 32388444 
  34. Levin-Epstein R, Qiao-Guan G, Juarez JE, Shen Z, Steinberg ML, Ruan D, Valle L, Nickols NG, Kupelian PA, King CR, Cao M, Kishan AU.   Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer.  Front Oncol. 2020 Apr 16;10:539. doi: 10.3389/fonc.2020.00539. eCollection 2020. PMID: 32373529
  35. Yoon S, Cao M, Aghdam N, Shabsovich D, Kahlon S, Ballas L, Collins S, Steinberg ML, Kishan AU.  Prostate bed and organ-at-risk deformation: Prospective volumetric and dosimetric data from a phase II trial of stereotactic body radiotherapy after radical prostatectomy.  Radiother Oncol. 2020 Jul;148:44-50. doi: 10.1016/j.radonc.2020.04.007. Epub 2020 Apr 9. PMID: 32311600 
  36. Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, Chen R, Choudhury A, Henry A, Syndikus I, Mitin T, Tree A, Kishan AU, Spratt DE. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19.  Adv Radiat Oncol. 2020 Apr 1;5(4):659-665. doi: 10.1016/j.adro.2020.03.010. eCollection 2020 Jul-Aug. PMID: 32292839
  37. Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, Mahal BA, Stish BJ, Zumsteg ZS, Den RB, Hall WA, Gharzai LA, Jaworski EM, Reichert ZR, Morgan TM, Mehra R, Schaeffer EM, Sartor O, Nguyen PL, Lee WR, Rosenthal SA, Michalski JM, Schipper MJ, Dignam JJ, Pisansky TM, Zietman AL, Sandler HM, Efstathiou JA, Feng FY, Shipley WU, Spratt DE.   Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.  JAMA Oncol. 2020 May 1;6(5):735-743. doi: 10.1001/jamaoncol.2020.0109. PMID: 32215583
  38. Kishan AU, Reiter RE.  Caught Between a Rock and a Hard Place.  Int J Radiat Oncol Biol Phys. 2020 Mar 12:S0360-3016(20)30223-6. doi: 10.1016/j.ijrobp.2020.01.053. Online ahead of print. PMID: 32173187  
  39. Zaorsky NG, Kishan AU.  Salvage therapy at biochemical recurrence of prostate cancer.  Nat Rev Urol. 2020 Apr;17(4):195-196. doi: 10.1038/s41585-020-0290-3. PMID: 32051611
  40. Inghrao K, Fu J, Wu HH, Hu P, Kishan AU, Chin RK, Lewis JH.   A novel anthropomorphic multimodality phantom for MRI-based radiotherapy quality assurance testing.  Med Phys. 2020 Apr;47(4):1443-1451. doi: 10.1002/mp.14027. Epub 2020 Mar 1. PMID: 31954078 
  41. Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, Nickols N, Rettig MB, Reiter RE, Czernin J, Calais J.   Impact of 68 Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. J Nucl Med. 2020 Aug;61(8):1153-1160. doi: 10.2967/jnumed.119.237602. Epub 2020 Jan 10. PMID: 31924715 
  42. Singhrao K, Ruan D, Fu J, Gao Y, Chee G, Yang Y, King C, Hu P, Kishan AU, Lewis JH.  Quantification of fiducial marker visibility for MRI-only prostate radiotherapy simulation. Phys Med Biol. 2020 Feb 5;65(3):035015. doi: 10.1088/1361-6560/ab65db. PMID: 31881546 
  43. Kishan AU, Chu FI, King CR, Seiferheld W, Spratt DE, Tran P, Wang X, Pugh SE, Sandler KA, Bolla M, Maingon P, De Reijke T, Nickols NG, Rettig M, Drakaki A, Liu ST, Reiter RE, Chang AJ, Feng FY, Sajed D, Nguyen PL, Kupelian PA, Steinberg ML, Boutros PC, Elashoff D, Collette L, Sandler HM.  Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. Eur Urol. 2020 Feb;77(2):201-208. doi: 10.1016/j.eururo.2019.10.008. Epub 2019 Nov 10. PMID: 31718822 
  44. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C Jr, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.   Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.  Eur Urol. 2020 Jan;77(1):3-10. doi: 10.1016/j.eururo.2019.03.022. Epub 2019 Apr 13. PMID: 30992160 
  45. Kishan AU, Collins SP, Nickols NG.  Optimal patient selection for stereotactic body radiotherapy.       Lancet Oncol. 2019 Dec;20(12):e661. doi: 10.1016/S1470-2045(19)30761-2. PMID: 31797787
  46. Expert Panel on Urological Imaging, Purysko AS, Nikolaidis P, Dogra VS, Ganeshan D, Gore JL, Gupta RT, Heilbrun ME, Khatri G, Kishan AU, Lyshchik A, Savage SJ, Smith AD, Wang ZJ, Wolfman DJ, Wong-You-Cheong JJ, Yoo DC, Lockhart ME.  ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Cancer.  J Am Coll Radiol. 2019 Nov;16(11S):S399-S416. doi: 10.1016/j.jacr.2019.05.022. PMID: 31685108 
  47. Wang C, Kishan AU, Yu JB, Raldow A, King CR, Iwamoto KS, Chu FI, Steinberg ML, Kupelian PA.  Association between Long-Term Second Malignancy Risk and Radiation: A Comprehensive Analysis of the Entire Surveillance, Epidemiology, and End Results Database (1973-2014).   Adv Radiat Oncol. 2019 May 15;4(4):738-747. doi: 10.1016/j.adro.2019.05.003. eCollection 2019 Oct-Dec. PMID: 31673667
  48. Wang C, Raldow AC, Nickols NG, Nguyen PL, Spratt DE, Dess RT, Yu JB, King CR, Chu FI, Chamie K, Litwin MS, Saigal CS, Reiter RE, Liu ST, Rettig MB, Chang AJ, Steinberg ML, Kupelian PA, Kishan AU.  Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer.  Eur Urol Oncol. 2019 Feb 1:S2588-9311(19)30007-0. doi: 10.1016/j.euo.2019.01.006. Online ahead of print. PMID: 31411981 
  49. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J.  18 F-fluciclovine PET-CT and 68 Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.  Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30. PMID: 31375469
  50. Jiang NY, Dang AT, Yuan Y, Chu FI, Shabsovich D, King CR, Collins SP, Aghdam N, Suy S, Mantz CA, Miszczyk L, Napieralska A, Namysl-Kaletka A, Bagshaw H, Prionas N, Buyyounouski MK, Jackson WC, Spratt DE, Nickols NG, Steinberg ML, Kupelian PA, Kishan AU.    Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy.   Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):628-636. doi: 10.1016/j.ijrobp.2019.06.2539. Epub 2019 Jul 2. PMID: 31276777 
  51. Kishan AU, Wang C, Steinberg ML, Spratt DE.  Key considerations when reviewing subsequent primary cancers following radiotherapy.  Lancet Oncol. 2019 Jun;20(6):e291. doi: 10.1016/S1470-2045(19)30227-X. PMID: 31162098
  52. Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M 3rd, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE.  Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.  JAMA Oncol. 2019 Jul 1;5(7):975-983. doi: 10.1001/jamaoncol.2019.0826. PMID: 31120534
  53. Yuan Y, Aghdam N, King CR, Fuller DB, Weng J, Chu FI, Mardirossian G, Patel A, Nickols NG, Kupelian PA, Steinberg ML, Collins SP, Kishan AU.  Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials.  Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):149-154. doi: 10.1016/j.ijrobp.2019.05.014. Epub 2019 May 17. PMID: 31108142 
  54. Dess RT, Soni PD, Jackson WC, Berlin A, Cox BW, Jolly S, Efstathiou JA, Feng FY, Kishan AU, Stish BJ, Pisansky TM, Spratt DE.   The current state of randomized clinical trial evidence for prostate brachytherapy.  Urol Oncol. 2019 Sep;37(9):599-610. doi: 10.1016/j.urolonc.2019.04.009. Epub 2019 May 3. PMID: 31060795   
  55. Kishan AU, Cook RR, King CR.  Reply to Marieke J. Krimphove, Junaid Nabi, Alexander P. Cole, and Quoc-Dien Trinh's Letter to the Editor re: Ronald D. Ennis, Liangyuan Hu, Shannon N. Ryemon, Joyce Lin, Madhu Mazumdar. Brachytherapy-based Radiotherapy and Radical Prostatectomy Are Associated with Similar Survival in High-risk Localized Prostate Cancer. J Clin Oncol 2018;36:1192-8: Setting the Standard: The Importance of Defining the Standard of Care for Comparative Effectiveness Analyses.  Eur Urol Oncol. 2019 Mar;2(2):224-225. doi: 10.1016/j.euo.2018.08.019. Epub 2018 Sep 10. PMID: 31017101
  56. Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, Gharzai LA, Jaworski EM, Mehra R, Hearn JWD, Morgan TM, Salami SS, Cooperberg MR, Mahal BA, Soni PD, Kaffenberger S, Nguyen PL, Desai N, Feng FY, Zumsteg ZS, Spratt DE.  Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.  Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):778-789. doi: 10.1016/j.ijrobp.2019.03.051. Epub 2019 Apr 6. PMID: 30959121
  57. Arikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG.    Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.  BMC Cancer. 2019 Apr 1;19(1):291. doi: 10.1186/s12885-019-5496-5. PMID: 30935383
  58. Kishan AU, Tyran M, Weng J, Upadhyaya S, Lamb J, Steinberg M, King C, Cao M. Stereotactic body radiotherapy to the prostate and pelvic lymph nodes: A detailed dosimetric analysis of a phase II prospective trial.  Br J Radiol. 2019 Jul;92(1099):20181001. doi: 10.1259/bjr.20181001. Epub 2019 Apr 3. PMID: 30912957
  59. Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N, Buyyounouski MK, Spratt DE, Linson PW, Hong RL, Nickols NG, Steinberg ML, Kupelian PA, King CR.   Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.  JAMA Netw Open. 2019 Feb 1;2(2):e188006. doi: 10.1001/jamanetworkopen.2018.8006. PMID: 30735235
  60. Kishan AU, Hall WA, Spratt DE.  Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019;75:552-5: Comparing Apples to Oranges: A Self-fulfilling Prophecy?  Eur Urol. 2019 May;75(5):e133-e134. doi: 10.1016/j.eururo.2019.01.016. Epub 2019 Jan 19. PMID: 30670312
  61. Ballas LK, Luo C, Chung E, Kishan AU, Shuryak I, Quinn DI, Dorff T, Jhimlee S, Chiu R, Abreu A, Jennelle R, Aron M, Groshen S.   Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy .                   Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):50-60. doi: 10.1016/j.ijrobp.2018.12.047. Epub 2018 Dec 31. PMID: 30605751
  62. Yuan Y, Kishan AU, Nickols NG.   Treatment of the primary tumor in metastatic prostate cancer.         World J Urol. 2019 Dec;37(12):2597-2606. doi: 10.1007/s00345-018-2552-8. Epub 2018 Nov 19. PMID: 30456709
  63. Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, Kupelian PA, Steinberg ML, King CR.  Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.  JAMA Oncol. 2019 Jan 1;5(1):91-96. doi: 10.1001/jamaoncol.2018.3732. PMID: 30326032
  64. Kishan AU, Tendulkar RD, Tran PT, Parker CC, Nguyen PL, Stephenson AJ, Carrie C.    Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer.  Eur Urol Oncol. 2018 May;1(1):3-18. doi: 10.1016/j.euo.2018.02.008. Epub 2018 May 15. PMID: 31100226       
  65. Dang A, Kupelian PA, Cao M, Agazaryan N, Kishan AU.  Image-guided radiotherapy for prostate cancer.  Transl Androl Urol. 2018 Jun;7(3):308-320. doi: 10.21037/tau.2017.12.37. PMID: 30050792
  66. Kishan AU, Cook RR, King CR.  Optimal Treatment for High-Risk Prostate Cancer-Reply.  JAMA. 2018 Jul 24;320(4):405. doi: 10.1001/jama.2018.6721. PMID: 30043055
  67. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.  Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.  Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):883-888. doi: 10.1016/j.ijrobp.2018.03.060. Epub 2018 Apr 5. PMID: 29976500 
  68. Hegde JV, Cao M, Yu VY, Kishan AU, Shaverdian N, Lamb J, Steinberg ML.  Magnetic Resonance Imaging Guidance Mitigates the Effects of Intrafraction Prostate Motion During Stereotactic Body Radiotherapy for Prostate Cancer.  Cureus. 2018 Apr 6;10(4):e2442. doi: 10.7759/cureus.2442. PMID: 29881655
  69. Kishan AU, Tyran M, Steinberg ML, Holden SB, Cao M.  MRI-guided Dose-escalated Salvage Radiotherapy for Bulky Bladder Neck Recurrence of Prostate Cancer.  Cureus. 2018 Mar 22;10(3):e2360. doi: 10.7759/cureus.2360. PMID: 29805929
  70. Alais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG.  Potential Impact of 68 Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.  J Nucl Med. 2018 Nov;59(11):1714-1721. doi: 10.2967/jnumed.118.209387. Epub 2018 Apr 13. PMID: 29653978
  71. Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR.   Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.  JAMA. 2018 Mar 6;319(9):896-905. doi: 10.1001/jama.2018.0587. PMID: 29509865
  72. O'Connell D, Shaverdian N, Kishan AU, Thomas DH, Dou TH, Lewis JH, Lamb JM, Cao M, Tenn S, Percy LP, Low DA.  Comparison of lung tumor motion measured using a model-based 4DCT technique and a commercial protocol.  Pract Radiat Oncol. 2018 May-Jun;8(3):e175-e183. doi: 10.1016/j.prro.2017.11.003. Epub 2017 Nov 11. PMID: 29429921 
  73. Nguyen T, Duong C, Sheppard JP, Lee SJ, Kishan AU, Lee P, Tenn S, Chin R, Kaprealian TB, Yang I.  Hypo-fractionated stereotactic radiotherapy of five fractions with linear accelerator for vestibular schwannomas: A systematic review and meta-analysis.  Clin Neurol Neurosurg. 2018 Mar;166:116-123. doi: 10.1016/j.clineuro.2018.01.005. Epub 2018 Jan 12. PMID: 29414150 
  74. Thomas DH, Santhanam A, Kishan AU, Cao M, Lamb J, Min Y, O'Connell D, Yang Y, Agazaryan N, Lee P, Low D.  Initial clinical observations of intra- and interfractional motion variation in MR-guided lung SBRT.  Br J Radiol. 2018 Feb;91(1083):20170522. doi: 10.1259/bjr.20170522. Epub 2018 Jan 22. PMID: 29166129
  75. Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.   68 Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.  J Nucl Med. 2018 Feb;59(2):230-237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9. PMID: 29123013
  76. Shaverdian N, Kishan AU, Veruttipong D, Demanes DJ, Kupelian P, McCloskey S, Steinberg ML, King CR.  Impact of the Primary Information Source Used for Decision Making on Treatment Perceptions and Regret in Prostate Cancer.  Am J Clin Oncol. 2018 Sep;41(9):898-904. doi: 10.1097/COC.0000000000000387. PMID: 28537990 
  77. Kishan AU, Duchesne G, Wang PC, Rwigema JM, Kishan AU, Saigal C, Rettig M, Steinberg ML, King CR.  Discord Among Radiation Oncologists and Urologists in the Postoperative Management of High-Risk Prostate Cancer.  Am J Clin Oncol. 2018 Aug;41(8):739-746. doi: 10.1097/COC.0000000000000381. PMID: 28301348 
  78. Kishan AU, Duchesne G, Wang PC, Rwigema JM, Saigal C, Rettig M, Steinberg ML, King CR.  Does Specialty Bias Trump Evidence in the Management of High-risk Prostate Cancer? Am J Clin Oncol. 2018 Jun;41(6):549-557. doi: 10.1097/COC.0000000000000323. PMID: 27560157 
  79. Kishan AU, Cheng EM, Schmidt E, Saigal C, Reiter RE, Kupelian PA, Steinberg ML, King CR. Use of the Electronic Medical Record to Facilitate Intervention for Patients With Rising Prostate-Specific Antigen Values After Radical Prostatectomy: A Feasibility Study.  JCO Clin Cancer Inform. 2017 Nov;1:1-6. doi: 10.1200/CCI.17.00046. PMID: 30657383 
  80. Hegde JV, Demanes DJ, Veruttipong D, Raince J, Park SJ, Raman SS, Nickols NG, King CR, Kishan AU, Steinberg ML, Kamrava M.  Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.  Brachytherapy. 2017 Nov-Dec;16(6):1106-1112. doi: 10.1016/j.brachy.2017.07.008. Epub 2017 Aug 12. PMID: 28807747
  81. Wang C, Kishan AU, Kamrava M, Steinberg ML, King CR.  External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.  Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1045-1052. doi: 10.1016/j.ijrobp.2017.03.040. Epub 2017 Mar 31. PMID: 28721887 
  82. Kishan AU, Voog JC, Wiseman J, Cook RR, Ancukiewicz M, Lee P, Ryan DP, Clark JW, Berger DL, Cusack JC, Wo JY, Hong TS.  Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease.  Br J Radiol. 2017 Aug;90(1076):20170134. doi: 10.1259/bjr.20170134. Epub 2017 Jun 14. PMID: 28613934
  83. Kishan AU, King CR.   Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer.  Semin Radiat Oncol. 2017 Jul;27(3):268-278. doi: 10.1016/j.semradonc.2017.02.006. Epub 2017 Feb 22. PMID: 2857783  
  84. Hegde JV, Veruttipong D, Said JW, Reiter RE, Steinberg ML, King CR, Kishan AU.  Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer.  Urology. 2017 Sep;107:171-177. doi: 10.1016/j.urology.2017.05.028. Epub 2017 May 25. PMID: 28552819
  85. Sandler KA, Shaverdian N, Cook RR, Kishan AU, King CR, Yang I, Steinberg ML, Lee P.    Treatment trends for patients with brain metastases: Does practice reflect the data?  Cancer. 2017 Jun 15;123(12):2274-2282. doi: 10.1002/cncr.30607. Epub 2017 Feb 8. PMID: 28178376 
  86. Shaverdian N, Verruttipong D, Wang PC, Kishan AU, Demanes DJ, McCloskey S, Kupelian P, Steinberg ML, King CR.  Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer.  Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):516-525. doi: 10.1016/j.ijrobp.2016.11.007. Epub 2016 Nov 24. PMID: 28126301 
  87. Kishan AU, Steinberg ML, Kupelian PA, King CR.   Reply to Thomas Van den Broeck, R. Jeffrey Karnes, and Steven Joniau's Letter to the Editor re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol 2017;71:766-73.  Eur Urol. 2017 Nov;72(5):e123-e124. doi: 10.1016/j.eururo.2017.01.017. Epub 2017 Jan 19. PMID: 28111115
  88. Kishan AU, Kupelian PA, Steinberg ML, King CR.     Urinary toxicity after stereotactic body radiotherapy: The boy who cried wolf?  Cancer. 2017 Feb 1;123(3):531-532. doi: 10.1002/cncr.30432. Epub 2016 Dec 20. PMID: 27997685
  89. Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR.   Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.  Eur Urol. 2017 May;71(5):766-773. doi: 10.1016/j.eururo.2016.06.046. Epub 2016 Jul 21. PMID: 27452951   
  90. Raghavan G, Kishan AU, Cao M, Chen AM.   Anatomic and dosimetric changes in patients with head and neck cancer treated with an integrated MRI-tri- 60 Co teletherapy device.  Br J Radiol. 2016 Nov;89(1067):20160624. doi: 10.1259/bjr.20160624. Epub 2016 Sep 21. PMID: 27653787
  91. Kishan AU, Lee P.   Radiation Therapy for Stage I Nonoperable or Medically Inoperable Lung Cancer.  Semin Respir Crit Care Med. 2016 Oct;37(5):716-726. doi: 10.1055/s-0036-1592113. Epub 2016 Oct 12. PMID: 27732993 
  92. Kishan AU, Gomez CL, Dawson NA, Dvorak R, Foster NM, Hoyt A, Hurvitz SA, Kusske A, Silver EL, Tseng C, McCloskey SA. Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary Clinic.  Ann Surg Oncol. 2016 Dec;23(Suppl 5):634-641. doi: 10.1245/s10434-016-5545-0. Epub 2016 Sep 12. PMID: 27619940 
  93. Kishan AU, Wang PC, Sharif J, Kupelian PA, Steinberg ML, McCloskey SA.    Clinical Indicators of Psychosocial Distress Predict for Acute Radiation-Induced Fatigue in Patients Receiving Adjuvant Radiation Therapy for Breast Cancer: An Analysis of Patient-Reported Outcomes.  Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):946-955. doi: 10.1016/j.ijrobp.2016.01.062. Epub 2016 Feb 11. PMID: 27105720 
  94. Modjtahedi BS, Bose N, Papakostas TD, Morse L, Vavvas DG, Kishan AU.   Lipids and Diabetic Retinopathy. Semin Ophthalmol. 2016;31(1-2):10-8. doi: 10.3109/08820538.2015.1114869. PMID: 26959124
  95. Kishan AU, Wang PC, Upadhyaya SK, Hauswald H, Demanes DJ, Nickols NG, Kamrava M, Sadeghi A, Kupelian PA, Steinberg ML, Prionas ND, Buyyounouski MK, King CR.  SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.    Pract Radiat Oncol. 2016 Jul-Aug;6(4):268-275. doi: 10.1016/j.prro.2015.11.002. Epub 2015 Nov 10. PMID: 26850649 
  96. Merna C, Rwigema JC, Cao M, Wang PC, Kishan AU, Michailian A, Lamb J, Sheng K, Agazaryan N, Low DA, Kupelian P, Steinberg ML, Lee P. A treatment planning comparison between modulated tri-cobalt-60 teletherapy and linear accelerator-based stereotactic body radiotherapy for central early-stage non-small cell lung cancer.  Med Dosim. 2016 Spring;41(1):87-91. doi: 10.1016/j.meddos.2015.09.002. Epub 2016 Jan 2. PMID: 26755076 
  97. Kishan AU, McCloskey SA.  Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available data.  Ther Adv Med Oncol. 2016 Jan;8(1):85-97. doi: 10.1177/1758834015617459. PMID: 26753007
  98. Kishan AU, Lee EW, McWilliams J, Lu D, Genshaft S, Motamedi K, Demanes DJ, Park SJ, Hagio MA, Wang PC, Kamrava M.  Image-guided high-dose-rate brachytherapy: preliminary outcomes and toxicity of a joint interventional radiology and radiation oncology technique for achieving local control in challenging cases.  J Contemp Brachytherapy. 2015 Oct;7(5):327-35. doi: 10.5114/jcb.2015.54947. Epub 2015 Oct 13. PMID: 26622237
  99. Kishan AU, Steinberg ML, Kupelian PA, King CR.  In Regard to Bauman et al.  Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1162-3. doi: 10.1016/j.ijrobp.2015.08.006. Epub 2015 Nov 11. PMID: 26581152
  100. Kishan AU, Park SJ, King CR, Roberts K, Kupelian PA, Steinberg ML, Kamrava M.  Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.  Br J Radiol. 2015;88(1056):20150658. doi: 10.1259/bjr.20150658. Epub 2015 Oct 14. PMID: 26463234
  101. Kishan AU, Cameron RB, Wang PC, Alexander S, Qi SX, Low DA, Kupelian PA, Steinberg ML, Lee JM, Selch MT, Lee P.  Tomotherapy improves local control and changes failure patterns in locally advanced malignant pleural mesothelioma.  Pract Radiat Oncol. 2015 Nov-Dec;5(6):366-73. doi: 10.1016/j.prro.2015.07.010. Epub 2015 Aug 1. PMID: 26432677 
  102. Kamrava M, Kishan AU, Margolis DJ, Huang J, Dorey F, Lieu P, Kupelian PA, Marks LS.  Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer.  Pract Radiat Oncol. 2015 Nov-Dec;5(6):411-6. doi: 10.1016/j.prro.2015.04.006. Epub 2015 Jun 6. PMID: 26059510
  103. Kishan AU, Cao M, Wang PC, Mikaeilian AG, Tenn S, Rwigema JM, Sheng K, Low DA, Kupelian PA, Steinberg ML, Lee P.   Feasibility of magnetic resonance imaging-guided liver stereotactic body radiation therapy: A comparison between modulated tri-cobalt-60 teletherapy and linear accelerator-based intensity modulated radiation therapy.  Pract Radiat Oncol. 2015 Sep-Oct;5(5):330-337. doi: 10.1016/j.prro.2015.02.014. Epub 2015 Mar 29. PMID: 25823383 
  104. Kishan AU, Lamb JM, Jani SS, Kang JJ, Steinberg ML, King CR.  Pelvic nodal dosing with registration to the prostate: implications for high-risk prostate cancer patients receiving stereotactic body radiation therapy.  Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):832-9. doi: 10.1016/j.ijrobp.2014.11.035. PMID: 25752398 
  105. Kishan AU, Cao M, Mikaeilian AG, Low DA, Kupelian PA, Steinberg ML, Kamrava M.  Dosimetric feasibility of magnetic resonance imaging-guided tri-cobalt 60 preoperative intensity modulated radiation therapy for soft tissue sarcomas of the extremity.  Pract Radiat Oncol. 2015 Sep-Oct;5(5):350-356. doi: 10.1016/j.prro.2015.01.007. Epub 2015 Mar 3. PMID: 25749215 
  106. Mesko S, Park SJ, Kishan AU, Demanes DJ, Kamrava M.   A sector-based dosimetric analysis of dose heterogeneity in high-dose-rate prostate brachytherapy.  Brachytherapy. 2015 Mar-Apr;14(2):173-8. doi: 10.1016/j.brachy.2014.11.009. Epub 2014 Dec 20. PMID: 25537448 
  107. Kishan AU, Kupelian PA.    Late rectal toxicity after low-dose-rate brachytherapy: incidence, predictors, and management of side effects.  Brachytherapy. 2015 Mar-Apr;14(2):148-59. doi: 10.1016/j.brachy.2014.11.005. Epub 2014 Dec 13. PMID: 25516492
  108. Kishan AU, Wang PC, Sheng K, Yu V, Ruan D, Cao M, Tenn S, Low DA, Lee P.  Correlation of Clinical and Dosimetric Parameters With Radiographic Lung Injury Following Stereotactic Body Radiotherapy.          Technol Cancer Res Treat. 2015 Aug;14(4):411-8. doi: 10.1177/1533034614551476. Epub 2014 Sep 26. PMID: 25261069